Takeda’ s Adcetris Wins “Landmark” Cancer Drugs Fund First In UK
Executive Summary
Takeda’s Adcetris has received expanded recommendations from England’s health technology appraisal institute, NICE, following data collected through the Cancer Drugs Fund.